BioTheranostics has received the go-ahead to distribute its Breast Cancer Index in New York. The molecular diagnostic assay measures a patient's risk of recurrent estrogen receptor-positive breast cancer and determines whether extended endocrine treatment will benefit the patient.
BioTheranostics gets OK to distribute breast cancer Dx in N.Y.
SmartBrief Job Listings for Health Care
|Director, Site Quality Management||
|In house Compliance Officer||
|Pompano Beach, FL|
|Clinical Project Manager||
|Sr. Manager, Regulatory Affairs - International||
|Associate - Food and Drug||
Keller and Heckman LLP